|
Market Closed -
Nasdaq
16:00:00 2026-09-23 EDT
|
5-day change | 1st Jan Change | ||
| 516.34 USD | +0.26% |
|
+0.33% | +13.89% |
| Market Cap | 131B 115B 108B 98.58B 184B 12,496B 185B 1,294B 501B 6,376B 490B 479B 20,660B | P/E 2026 * |
53.1x | P/E 2027 * | 28x |
|---|---|---|---|---|---|
| Enterprise Value | 126B 111B 104B 95.35B 178B 12,086B 179B 1,252B 485B 6,167B 474B 464B 19,983B | EV / Sales 2026 * |
9.53x | EV / Sales 2027 * | 8.45x |
| Free-Float |
99.79% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| VRTX | Delayed | |
CBOE
| VRTX | Real-time | |
|
Tradegate
| VX1 | Real-time | |
|
Deutsche Boerse AG
| VX1 | Delayed | |
|
Mexican S.E.
| VRTX * | End-of-day quote | |
|
Xetra
| VX1 | Delayed | |
|
Boerse Muenchen
| VX1 | Real-time | |
|
Börse Stuttgart
| VX1 | Delayed | |
|
CBOE
| Real-time | ||
|
London S.E.
| 0QZU | Delayed | |
|
Wiener Boerse
| VRTX | End-of-day quote | |
|
Borsa Italiana
| 1VRTX | End-of-day quote | |
|
CBOE
| 0QZU | Real-time |
Last Transcript: Vertex Pharmaceuticals Incorporated
| 1 day | +0.26% | ||
| 1 week | +0.33% | ||
| Current month | -5.18% | ||
| 1 month | -5.79% | ||
| 3 months | +10.62% | ||
| 6 months | +13.73% | ||
| Current year | +13.89% |
| 1 week | 501.01 |  | 525.97 |
| 1 month | 501.01 | | 560.25 |
| Current year | 412.27 | | 560.25 |
| 1 year | 374.17 | | 560.25 |
| 3 years | 341.85 | | 560.25 |
| 5 years | 176.36 | | 560.25 |
| 10 years | 71.46 | | 560.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 2020-03-31 | |
Charles Wagner
DFI | Director of Finance/CFO | 57 | 2019-04-09 |
Sean Daughtry
CTO | Chief Tech/Sci/R&D Officer | - | 2024-02-29 |
| Director | Title | Age | Since |
|---|---|---|---|
Bruce Sachs
BRD | Director/Board Member | 66 | 1997-12-31 |
Jeffrey Leiden
CHM | Chairman | 70 | 2012-04-30 |
Sangeeta Bhatia
BRD | Director/Board Member | 57 | 2015-06-17 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/28/26 | Free | Controller/Auditor | 5,000 | 0.0020% | ||
| 8/27/26 | Don | Director | -6,000 | 0.0024% | ||
| 7/21/26 | Free | General Counsel | 8,251 | 0.0033% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.26% | +0.33% | +34.77% | +47.72% | 131B | |
| -1.64% | +1.31% | +52.46% | +109.07% | 1,043B | |
| -0.01% | +0.74% | +54.51% | +67.71% | 649B | |
| -0.05% | +0.78% | +19.09% | +73.55% | 469B | |
| -0.25% | +0.72% | +33.97% | +45.63% | 355B | |
| +0.98% | +3.30% | +19.63% | +27.91% | 270B | |
| -1.91% | +2.59% | +8.09% | +12.53% | 262B | |
| -1.01% | +8.10% | +41.99% | +51.70% | 222B | |
| -0.85% | +3.47% | +34.56% | +101.80% | 189B | |
| -2.53% | -8.57% | -34.17% | -60.67% | 175B | |
| Average | -0.06% | +1.98% | +26.49% | +47.69% | 376.36B | |
| Weighted average by Cap. | +0.20% | +2.11% | +35.31% | +65.22% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 13.25B 11.64B 10.93B 10B 18.67B 1,268B 18.82B 131B 50.85B 647B 49.73B 48.66B 2,097B | 14.55B 12.78B 12B 10.99B 20.51B 1,393B 20.67B 144B 55.84B 711B 54.61B 53.43B 2,302B |
| Net income | 2.53B 2.23B 2.09B 1.91B 3.57B 243B 3.6B 25.14B 9.73B 124B 9.52B 9.31B 401B | 4.83B 4.25B 3.99B 3.65B 6.81B 463B 6.87B 47.93B 18.55B 236B 18.14B 17.75B 765B |
| Net Debt | -4.28B -3.76B -3.53B -3.23B -6.03B -409B -6.08B -42.42B -16.42B -209B -16.06B -15.71B -677B | -7.54B -6.62B -6.22B -5.69B -10.63B -722B -10.71B -74.77B -28.94B -368B -28.31B -27.7B -1,193B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-23 | US$516.36 | +0.27% | 1,185,105 |
| 26-09-22 | US$514.99 | +0.84% | 1,386,645 |
| 26-09-21 | US$510.72 | +0.47% | 906,681 |
| 26-09-18 | US$508.34 | -1.55% | 2,434,832 |
| 26-09-17 | US$516.34 | +0.60% | 900,049 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VRTX Stock
Select your edition
All financial news and data tailored to specific country editions
